EN DE
Watch Neuland Laboratories Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Neuland Laboratories Limited (NEULANDLAB) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Neuland Laboratories Limited stock ₹5,987, price ₹21,640, that is 72.3% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE794A01010

NL Neuland Laboratories Limited logo Broad data Nov 12, 2026

Neuland Laboratories Limited

NEULANDLAB · NSE

Far too expensive (fair value 72% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Solidly profitable · 19.6% net margin (TTM) 
Low debt 
Wide moat 73/100
Broad data 
Quality 55/100 
Expensive Growth (revenue 5y +17.1 %/yr in INR) 
Revenue last quarter 11% below a year ago. 
Fair value ₹5,987 · Strongly overvalued 
Negative free cash flow 
Trails peers (5/13) 
Watch Neuland Laboratories Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹23,995 ₹961.69 Fair Value ₹5,987 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range ₹961.69 – ₹23,995 · fair‑value band ₹4,191 – ₹7,783 · the ₹21,640 price screens above the ₹5,987 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Neuland Laboratories in your weekly email

Every Wednesday you see whether Neuland Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services.

Show moreShow less

Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Stock analysis

Neuland Laboratories Limited (NEULANDLAB) currently trades at ₹21,640, while our model-based Fair Value estimate is ₹5,987, 72% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹5,987 per share, and 0 of the 16 models we run sit above the ₹21,640 price.

Bear case: the Economic Profit group reads lowest at ₹2,835, and 16 of the 16 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹4,191 (bear) to ₹7,783 (bull), the price of ₹21,640 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Neuland Laboratories Limited reported revenue of ₹20.2B in FY2026 versus ₹9.2B in FY2022, a compound +21.7%/yr. Reported net income was ₹3.6B in FY2026, compounding +54.5%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.

Key figures

Market cap ₹278B (≈ $2.9B) Mid · P/E ratio 61.4 · P/S ratio 12.0 · EPS (TTM) ₹352.72 · Dividend yield 0.1% · Net margin 19.6% · Return on equity 24.8% · Return on assets (EBIT) 14.5% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (medium confidence).

What moves the price

The share trades about 10% below its 52-week high and 88% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −72%, NEULANDLAB screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (₹155.88 to ₹9,976). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹4,191 Fair Value ₹5,987 Bull ₹7,783
Price ₹21,640 · Downside -72.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹222.26 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV ₹2,409 ₹2,721 ₹2,982 74
Residual Income ₹1,607 ₹2,218 ₹3,935 73
ROIC Compounder ₹2,692 ₹3,452 ₹4,393 72
All 16 models by family
Earnings-Based
Graham-Dodd ₹1,929 ₹9,976 ₹13,793 64
Lynch FV ₹2,787 ₹3,981 ₹5,175 61
PEG = 1.0 ₹2,787 ₹3,981 ₹5,175 57
EPV ₹2,409 ₹2,721 ₹2,982 74
Dividend Discount
Gordon GGM ₹94.32 ₹171.43 ₹237.76 68
DDM Multi-Stage ₹94.32 ₹155.88 ₹182.96 67
Multiples
P/E Multiple ₹4,681 ₹6,242 ₹7,802 63
P/S Multiple ₹3,617 ₹4,823 ₹6,029 58
P/B Multiple ₹2,950 ₹3,933 ₹4,916 55
EV/EBIT ₹4,839 ₹6,439 ₹8,038 66
EV/EBITDA ₹4,744 ₹6,311 ₹7,878 67
EV/Revenue ₹3,353 ₹4,772 ₹6,191 53
Asset-Based
NCAV (Graham) ₹219.90 ₹333.18 ₹416.47 54
Economic Profit
Residual Income ₹1,607 ₹2,218 ₹3,935 73
ROIC Compounder ₹2,692 ₹3,452 ₹4,393 72
Growth Earnings
Growth-Adj P/E ₹4,191 ₹5,987 ₹7,783 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 62
How much profit the company makes from its sales and capital
Quality Growth 56
Are margins and returns getting better?
Cashflow 24
Do the profits arrive as real cash?
Financial strength 87
Debt, balance sheet and risk of trouble
Investment 1
Does it invest with discipline instead of growing at any price?
Low Volatility 76
How calm the share price moves, does not count
Price momentum 56
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 71
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+41.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Start year 2021 (pandemic). Over 10 years: +14.8% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.4%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+41.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+41.7%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.41.7% vs 24.9%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 24%
Pace: the 5-year rate starts in 2021 (pandemic)

NEULANDLAB screens overvalued: fair value 72% below the price. Compare with Merck KGaA →

Compare Neuland Laboratories Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside −72.3% · Bottom 25%
Profitability
Return on equity (12 months) 24.8% · Top 25%
Return on assets 12.4% · Top 25%
Net margin (12 months) 19.6% · Top 25%
Operating margin (12 months) 16.7% · Above median
Growth and dividend
Revenue growth (quarter YoY) −11.1% · Bottom 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 61.4× · Priciest 25%
P/B 14.81× · Priciest 25%
P/S (12 months) 12.00× · Priciest 25%
EV/EBITDA 39.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)99 · sector 26
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)1 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Neuland Laboratories Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Neuland Laboratories Limited Fair Value". https://www.fairvalue-calculator.com/stock/NEULANDLAB

Frequently asked questions

Is Neuland Laboratories Limited (NEULANDLAB) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of ₹5,987 versus a price of ₹21,640, about 72% lower (overvalued).
What is the fair value of NEULANDLAB?
Our model-based fair value for Neuland Laboratories Limited is ₹5,987 (as of Nov 12, 2026), built from audited fundamentals. The current price: ₹21,640.
What is the quality score of NEULANDLAB?
Neuland Laboratories Limited has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neuland Laboratories Limited (NEULANDLAB)?
Our model-based price target is the fair value of ₹5,987 (as of Nov 12, 2026) from 16 valuation models. Cautious scenario ₹4,191, optimistic scenario ₹7,783. It is a calculation from audited fundamentals, not an analyst target.
What is the Neuland Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹5,987, about 72% lower versus a price of ₹21,640 (overvalued). Cautious scenario ₹4,191, optimistic scenario ₹7,783. The calculation is refreshed regularly with new filings.
What is the revenue of Neuland Laboratories Limited (NEULANDLAB)?
Neuland Laboratories Limited reported trailing-twelve-month revenue of about ₹23.1B (latest available figure, as of Nov 12, 2026).
Does Neuland Laboratories Limited pay a dividend?
Neuland Laboratories Limited currently shows a dividend yield of 0.06% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of Neuland Laboratories Limited (NEULANDLAB)?
Neuland Laboratories Limited has a dividend yield of 0.1%.
What is the intrinsic value of Neuland Laboratories Limited (NEULANDLAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neuland Laboratories Limited it is ₹5,987 per share (as of Nov 12, 2026), against a price of ₹21,640. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Neuland Laboratories Limited stock overvalued or undervalued in 2026?
As of Nov 12, 2026, NEULANDLAB trades above its calculated fair value: price ₹21,640, fair value ₹5,987, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NEULANDLAB?
No. The price is what the market pays today (₹21,640); the fair value is what the company's own numbers justify (₹5,987). For Neuland Laboratories Limited the two are ₹15,653 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neuland Laboratories Limited worth?
The market values Neuland Laboratories Limited at about ₹278B (market capitalisation, as of Nov 12, 2026). Per share that is ₹21,640; our models calculate a fair value of ₹5,987 per share.
What do the bullish and bearish scenarios say about NEULANDLAB?
Our models span a range for Neuland Laboratories Limited: cautious scenario ₹4,191, base ₹5,987, optimistic ₹7,783 per share (as of Nov 12, 2026, price ₹21,640). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NEULANDLAB?
Neuland Laboratories Limited trades at a price-to-earnings ratio of 61.4 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹5,987 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 34.4. Other multiples: P/B 14.8, P/S 12.0, EV/EBITDA 39.2.
How solid is the balance sheet of Neuland Laboratories Limited (NEULANDLAB)?
Balance-sheet figures for Neuland Laboratories Limited (as of Nov 12, 2026): return on equity 24.8%, debt of 0.09 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is NEULANDLAB from its 52-week high?
Neuland Laboratories Limited trades at ₹21,640, about 10% below its 52-week high of ₹23,995 and 88% above the low of ₹11,534 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹5,987 is for.
Which stocks are comparable to Neuland Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neuland Laboratories Limited stock attractive at the current price?
The data as of Nov 12, 2026: price ₹21,640, calculated fair value ₹5,987 (−72%), Quality Score 55/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NEULANDLAB calculated?
We run Neuland Laboratories Limited through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹5,987 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Neuland Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neuland Laboratories Limited (NEULANDLAB)?
The closing price on Nov 16, 2026 was ₹21,640. Our model-based fair value is ₹5,987, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neuland Laboratories Limited right now?
The price sits above even our optimistic bull case (₹7,783). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹4,191 to ₹7,783) leaves room in how you read the outcome.
Where does the earnings growth of Neuland Laboratories Limited (NEULANDLAB) come from?
Earnings per share at Neuland Laboratories Limited grew 25.3 % a year from 2015 to 2026. Broken into its drivers: revenue per share +10.2 %, EBIT margin +6.4 %, tax rate +1.2 %, residual (interest, one-offs) +5.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Neuland Laboratories Limited

How large is the market capitalisation of Neuland Laboratories Limited (NEULANDLAB)?
The market capitalisation of Neuland Laboratories Limited is ₹278B (≈ $2.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neuland Laboratories Limited (NEULANDLAB)?
The price-to-sales ratio of Neuland Laboratories Limited is 12.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neuland Laboratories Limited (NEULANDLAB)?
Earnings per share at Neuland Laboratories Limited are ₹352.72 (price ÷ EPS = P/E 61.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Neuland Laboratories Limited (NEULANDLAB)?
The dividend yield of Neuland Laboratories Limited is 0.1% (payout 3.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Neuland Laboratories Limited (NEULANDLAB)?
The net margin of Neuland Laboratories Limited is 19.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neuland Laboratories Limited (NEULANDLAB)?
The return on equity (ROE) of Neuland Laboratories Limited is 24.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neuland Laboratories Limited (NEULANDLAB)?
On an EBIT basis the return on assets of Neuland Laboratories Limited is 14.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neuland Laboratories Limited (NEULANDLAB)?
The operating margin of Neuland Laboratories Limited is 16.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neuland Laboratories Limited (NEULANDLAB)?
Revenue at Neuland Laboratories Limited is down 11.1% versus a year earlier (3y avg +20.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Neuland Laboratories Limited (NEULANDLAB)?
Earnings per share at Neuland Laboratories Limited are down 46.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Neuland Laboratories Limited (NEULANDLAB) generate?
The free cash flow of Neuland Laboratories Limited is −₹589M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Neuland Laboratories Limited (NEULANDLAB) hold?
Neuland Laboratories Limited holds more cash than debt, ₹537M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Neuland Laboratories Limited in the live analysis

One click puts Neuland Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.